Elliott Nickbarg

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also affiliated with Quantitative BioSciences

Biochemistry, Genetics and Molecular BiologyComputer ScienceNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus”.

Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00717-23

N/A

0DataRank · unranked

15 citations

Dereje A. Negatu, Christopher J. Bungard, Véronique Dartois, Abdellatif El Marrouni, Elliott Nickbarg +4 more

Targeting RNA with small molecules: lessons learned from Xist RNA

RNA(2023)10.1261/rna.079523.122

N/A

0DataRank · unranked

11 citations

Kerrie B. Spencer, Jonathan D. Mortison, Jeannie T. Lee, Elliott Nickbarg